The most serious and common adverse drug reactions reported with agalsidase beta are infusion-related, consisting primarily of fever and chills or rigors, as well as tachycardia, hypertension, tightness of the throat, chest pain or tightness, dyspnea, abdominal pain, pruritus, urticaria, nausea and vomiting, lip or ear edema, and rash. These reactions occurred during the infusion [...]
Continue reading " Agalsidase beta: SAFETY AND CONTRAINDICATIONS "
Eng et al.,2001 Eng et al. evaluated agalsidase beta in a phase 1/2, single-center, open-label, dose-ranging study involving 15 patients with Fabry disease. The patients received one infusion of agalsidase beta at different dosage regimens for a total of five infusions. Results demonstrated a mean decrease in the GL-3 content of the liver by 84%, [...]
BACKGROUND Fabry disease is a rare X-linked lysosomal disorder caused by a deficiency of the enzyme alpha-galactosidase A. This deficiency results in progressive accumulation of glyco-sphingolipids, especially globotriaosylceramide (GL-3), in numerous tissues, particularly in the vascular endothelium throughout the body. Clinical manifestations of GL-3 accumulation include skin lesions; hypohidrosis; neuropathy; gastrointestinal problems, including diarrhea and [...]
